This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

10 Alzheimer's Disease Treatment Stocks

BOSTON ( TheStreet) -- Scientists are making great strides toward developing new tests enabling the early diagnosis of Alzheimer's disease, perhaps even before patients start exhibiting the loss of memory and cognitive function that are the terrible hallmarks of the neuro-degenerative disease.

Coming up with drugs to effectively treat or even reverse Alzheimer's is proving to be much a more elusive goal, unfortunately.

Tuesday's announcement by Eli Lilly (LLY) that Alzheimer's patients treated with its experimental drug semagacestat were performing worse than placebo patients in two late-stage studies. (forcing Lilly to stop the studies) was just the latest in a string of negative results from Alzheimer's drug trials.

Other recent Alzheimer's late-stage drug study failures have tripped up the partnership between Pfizer (PFE) and Medivation (MDVN), Myriad Genetics (MYGN) and the now-defunct Neurochem. A drug owned by Elan (ELN) and Wyeth (since bought by Johnson& Johnson (JNJ)) and another controlled by Elan and Transition Therapeutics (TTHI) are being studied in ongoing phase III studies despite what might be optimistically called mixed phase II results.

Long term, recently announced breakthroughs involving new brain imaging techniques and the discovery of biomarkers for Alzheimer's might allow scientists to learn more about the causes of Alzheimer's. Along with new diagnostics, the scientific consensus seems to be moving towards designing clinical trials that target patients in early-stage Alzheimer's patients, or even patients with pre-Alzheimer's, which may give drugs a better chance for success.

Meantime, drug companies forge ahead with Alzheimer's clinical trials. Perhaps one of the drugs listed below will succeed where so many others have failed. After Tuesday's bad news from Lilly, investors seeking Alzheimer's gold could use some cheering up.

Ten Alzheimer's Disease Drugs in Mid- to Late-Stage Clinical Trials:

Pfizer and Medivation
Drug: Dimebon
Drug type: Mitochondrial
Stage: Phase III
Dimebon failed a phase III monotherapy study that enrolled patients with mild to moderate Alzheimer's. An additional phase III study is still in progress: The "Concert" trial is studying the combination of Dimebon plus Aricept in patients with mild to moderate Alzheimers. Results are expected in 2012. Pfizer and Medivation are also conducting a phase III study of Dimebon in Huntington's disease, with results expected in the first half of 2011.

Johnson & Johnson (with minority partners Pfizer and Elan)
Drug: bapineuzumab
Drug type: Amyloid beta
Stage: Phase III
Lackluster data released in 2009 from a closely watched phase II study has cast a long shadow over bapineuzumab's development. Most recently, Johnson & Johnson said top-line results from pivotal, phase III studies in mild to moderate Alzheimer's patients wouldn't be ready until the end of 2012, a pushback from 2011.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs